Clinical Trials Logo

Clinical Trial Summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.


Clinical Trial Description

Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06314529
Study type Observational
Source Bioray Laboratories
Contact Xiaochen Wang, PhD
Phone 021-64340008
Email xcwang@brlmed.com
Status Recruiting
Phase
Start date December 14, 2022
Completion date May 10, 2037

See also
  Status Clinical Trial Phase
Recruiting NCT05799118 - Study of the Role of Genetic Modifiers in Hemoglobinopathies
Completed NCT06153784 - Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients Phase 2/Phase 3
Completed NCT05132270 - Clinical Experience of Thalidomide in Thalassemic Patients Phase 2/Phase 3
Recruiting NCT05736419 - A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Phase 2
Not yet recruiting NCT06298630 - Long-term Follow-up Study of BRL-101 for TDT
Recruiting NCT06041620 - Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells N/A
Recruiting NCT03183375 - The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan Phase 2